Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Wuhan YZY Biopharma Co's total inventories for the quarter that ended in Dec. 2025 was HK$3.63 Mil. Wuhan YZY Biopharma Co's average total inventories from the quarter that ended in Jun. 2025 to the quarter that ended in Dec. 2025 was HK$3.83 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Wuhan YZY Biopharma Co's Net-Net Working Capital per share for the quarter that ended in Dec. 2025 was HK$-0.67.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Wuhan YZY Biopharma Co's Days Inventory for the
six
months ended in Dec. 2025 was 23.75.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Wuhan YZY Biopharma Co's Inventory Turnover for the quarter that ended in Dec. 2025 was 7.68.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Wuhan YZY Biopharma Co's Inventory-to-Revenue for the quarter that ended in Dec. 2025 was 0.12.
Wuhan YZY Biopharma Co (HKSE:02496) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Wuhan YZY Biopharma Co's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2025 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Wuhan YZY Biopharma Co's Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Wuhan YZY Biopharma Co Total Inventories Related Terms
Wuhan YZY Biopharma Co Total Inventories Historical Data
* Premium members only.
The historical data trend for Wuhan YZY Biopharma Co's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wuhan YZY Biopharma Co Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
What does a Total Inventories of HK$3.63 Mil mean?
Wuhan YZY Biopharma Co (HKSE:02496) has a Total Inventories of HK$3.63 Mil as of Dec. 2025. The total amount of inventory as recorded on a company's balance sheet. View historical data for Wuhan YZY Biopharma Co and its competitors.
Is Wuhan YZY Biopharma Co's Total Inventories too high?
Wuhan YZY Biopharma Co's current Total Inventories is HK$3.63 Mil.
How does Wuhan YZY Biopharma Co's Total Inventories compare to VRTX and REGN?
Wuhan YZY Biopharma Co's Total Inventories of HK$3.63 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Wuhan YZY Biopharma Co and its competitors. Wuhan YZY Biopharma Co's current Total Inventories is HK$3.63 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuhan YZY Biopharma Co stock overvalued right now?
Wuhan YZY Biopharma Co (HKSE:02496) has a current Total Inventories of HK$3.63 Mil. The current Total Inventories is HK$3.63 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Wuhan YZY Biopharma Co (HKSE:02496), the current Total Inventories is HK$3.63 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Wuhan YZY Biopharma Co Ltd is a biotechnology company dedicated to developing bispecific antibody (BsAb)- based therapies. The Company has been forward-looking in deploying its presence in several therapeutic fields, including but not limited to tumor-associated complications, tumors, ophthalmology, and autoimmune diseases. The Company also proactively established several self-developed technology platforms, such as Y-BODY, Check-Body, and Nano-Ybody, promoting the development of more candidates to clinical stages with high efficiency.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02496 has been successfully added to your 
